1448309-79-2

Upstream product

• 144978-35-8 (S)-ethyl N-tert-butoxycarbonylpyroglutamate 
• 913251-58-8 (S)-2-(tert-butoxycarbonylamino)-5-oxohexanoic acid ethyl ester 
• 1448310-17-5 (S)-ethyl 5-methyl-3,4-dihydro-2H-pyrrole-2-carboxylate 2,2,2-trifluoro acetate salt 
• 676560-85-3 (2S,5S)-ethyl 5-methylpyrrolidine-2-carboxylate 2,2,2-trifluoro acetate salt 
• 1448310-18-6 (2S,5S)-ethyl 5-methyl-1-(pyrimidin-2-yl)pyrrolidine-2-carboxylate 
• 1000698-98-5 1,1-difluoro-4-isocyanocyclohexane 
• 1448310-19-7 (2S,5S)-5-methyl-1-(pyrimidin-2-yl)pyrrolidine-2-carboxylic acid 
• 1273566-51-0 C₆H₁₂FN 
• 89-98-5 2-chloro-benzaldehyde 

Relevant academic research and scientific papers

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.